7.13 +1.73 (32.64%)
CLVS
| Trade CLVS now with |
Stock Details
Last Trade:7.13 Change:+1.73 (32.64%) Prev Close:5.40 Open: 5.30 Days Range:5.15 – 7.70 52 Week Range: 11.57 - 40.29 Volume:23249881 P/E: N/AEPS:-2.82
View AllRecent Alerts 03/28/20
Recent Alert on 03/03/20 at 8:30am
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology to Present at the Barclays Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2020 at 11:15... Read More
Recent Alert on 03/02/20 at 4:00am
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain
Recent Alert on 02/25/20 at 9:21am
Pre-Open Stock Movers 2/25: (MNK) (LL) (MRNA) Higher (TUP) (PANW) (SHAK) Lower (more...)
Pre-Open Stock Movers 2/25: (MNK) (LL) (MRNA) Higher (TUP) (PANW) (SHAK) Lower (more...)
Recent Alert on 02/24/20 at 5:57pm
After-Hours Stock Movers 02/24: (MRNA) (MMSI) (NLS) Higher; (PANW) (EVER) (SHAK) Lower (more...)
After-Hours Stock Movers 02/24: (MRNA) (MMSI) (NLS) Higher; (PANW) (EVER) (SHAK) Lower (more...)
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 08/01/13 at 2:44pm
Clovis Oncology CEO Discusses Q2 2013 Results - Earnings Call Transcript
Clovis Oncology CEO Discusses Q2 2013 Results - Earnings Call Transcript
Blog Posts on 06/18/13 at 8:01am
Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market
Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market